Acelyrin

Lonigutamab shows promise for Thyroid Eye Disease (TED) with efficacy comparable to standard care and a favorable safety profile. Phase 3 trials, LONGITUDE-1 and LONGITUDE-2, are set to begin in Q1 2025, with topline data expected in late 2026. The drug demonstrated significant improvements in TED symptoms without adverse effects like hearing impairment or hyperglycemia.

ACELYRIN, INC. announced Phase 2 data showing lonigutamab's efficacy and safety in Thyroid Eye Disease (TED), with Phase 3 trials starting Q1 2025. Data expected H2 2026. Lonigutamab shows promise for a safer, effective TED treatment, with no reported hearing impairment or hyperglycemia.

ACELYRIN, INC. advances lonigutamab into Phase 3 trials for Thyroid Eye Disease (TED) after promising Phase 2 results. The drug, a monoclonal antibody targeting IGF-1 receptor, shows robust efficacy and a better safety profile. Phase 3 trials, LONGITUDE, to start in Q1 2025, aim to confirm safety and efficacy, with topline data expected in late 2026. ACELYRIN's financial health is strong, with cash extending through mid-2027.

Acelyrin (SLRN) revealed Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), showing significant improvements in symptoms. A Phase 3 program, LONGITUDE, is set to start this quarter, with topline data expected in 2026. It includes two global trials evaluating a 100 mg loading dose followed by 50 mg every two weeks, focusing on proptosis response rate at 24 weeks.

Lonigutamab shows promise for Thyroid Eye Disease (TED) with efficacy comparable to standard care and a favorable safety profile. ACELYRIN plans Phase 3 trials starting Q1 2025, with data expected in late 2026. The Phase 3 LONGITUDE program aims to address unmet needs in TED treatment.

ACELYRIN, INC. announced Phase 2 data showing lonigutamab's efficacy in Thyroid Eye Disease (TED) with significant proptosis response and no adverse effects reported. The Phase 3 LONGITUDE program, starting this quarter, will evaluate lonigutamab's safety and efficacy in 350 patients across two trials, with primary endpoints focusing on proptosis response at 24 weeks.

Lonigutamab shows promise for Thyroid Eye Disease (TED) with efficacy comparable to standard care and a favorable safety profile. Phase 3 trials, LONGITUDE-1 and 2, are set to begin in Q1 2025, with topline data expected in late 2026. The trials aim to assess the safety and efficacy of a subcutaneous dose, focusing on proptosis response rate at 24 weeks.

ACELYRIN, INC. announced Phase 2 data showing lonigutamab's efficacy in Thyroid Eye Disease (TED) with a favorable safety profile. A Phase 3 program, LONGITUDE, is set to start in Q1 2025, with topline data expected in H2 2026. The company will host a conference call on January 6, 2025, to discuss these findings.

ACELYRIN, INC., a late-stage clinical biopharma company, focuses on developing transformative medicines. Its lead candidate, izokibep, targets immunologic conditions like HS, PsA, and uveitis. It also develops Lonigutamab for TED and SLRN-517 for chronic urticaria, aiming to provide innovative treatment options.

ACELYRIN announced Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), showing efficacy and safety. Plans for Phase 3 trials starting Q1 2025, with topline data expected in 2026. Lonigutamab offers a potential safer, effective alternative to current treatments.